The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.25
Bid: 2.00
Ask: 2.50
Change: -1.25 (-35.71%)
Spread: 0.50 (25.00%)
Open: 1.875
High: 2.25
Low: 1.75
Prev. Close: 3.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Genedrive Performance Data in Gut

10 Apr 2018 07:00

RNS Number : 3380K
Genedrive PLC
10 April 2018
 

For release: 10 April 2018

 

genedrive plc ("genedrive" or the "Company")

 

Publication of Genedrive® Hepatitis C Test Performance Data in BMJ Gut

 

Studies in UK, France and South Africa showed >98% sensitivity and 100% specificity across all major HCV genotypes

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces the publication of analytical performance and field evaluation studies of its Genedrive® HCV ID Kit in Europe and Africa in the prestigious BMJ Gut, a leading international journal in gastroenterology and hepatology[1].

 

The paper is available to view online at: http://gut.bmj.com/content/gutjnl/early/2018/04/03/gutjnl-2017-315783.full.pdf

 

The publication reports on assay performance data generated and used for Genedrive®'s CE-IVD certification, including analytical performance data as well as field performance evaluation. Field performance evaluation studies were performed in Europe by the Institut Pasteur, Paris and Queen's Medical Centre, Nottingham, and in Johannesburg, South Africa by Lancet Laboratories, a commercial clinical facility providing testing services for patients from South Saharan countries.

 

Pan-genotype performance, with excellent exclusivity for non-HCV pathogens and sensitivity of greater than 98% and specificity of 100% in samples of European and African origin (including South Africa, Kenya, Ghana, Nigeria, Uganda is reported), was observed. The test was validated in a real clinical setting in a resource-limited country.

 

The paper concluded that Genedrive® HCV ID Kit was a rapid, simple, portable and accurate near patient molecular test for HCV, with sensitivity and specificity that fulfils the recent FIND/WHO target Product Profile for HCV decentralised testing in low income and middle-income countries.

 

David Budd, Chief Executive Officer of genedrive plc., commented: "This high impact peer reviewed publication provides further validation of the performance of our Genedrive® HCV ID assay. We are first to market with a decentralised qualitative molecular HCV test for use at point of need and believe we have the potential to positively impact the continuum of care from screening to cure by supporting real-time treatment decisions."

 

Dr Darragh Duffy of the Institut Pasteur, said: "Whilst direct acting antiviral therapies have revolutionised therapeutic options for treating HCV patients, the challenge remains to identify people infected with the virus, many of whom are living in geographic regions that lack access to state-of-the-art diagnostics. We are proud to have partnered with genedrive through our EU Framework 7 funded POC-HCV consortium to aid realisation of this rapid point of need test that enables real-time treatment and management of chronic HCV patients in decentralised settings, and to have seen our work published in this prestigious journal following extensive peer review."

 

genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India. genedrive recently announced first commercial sales of instruments and assays in Africa and Asia Pacific, excluding India.

 

- Ends -

 

 

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

Matthew Fowler: CFO

 

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

Stanford Capital Partners Limited +44 (0)203 815 8880

Patrick Claridge

 

Institut Pasteur Press office

MYRIAM REBEYROTTE +33 (0)1 45 68 81 01

AURELIE PERTHUISON +33 (0)1 45 68 89 28

presse@pasteur.fr

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.

 

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

About Hepatitis C

Hepatitis C is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic hepatitis C, and more than 350,000 people die yearly from hepatitis C related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate Hepatitis C.

 

 

 

 

 


[1] Llibre A, Shimakawa Y, Mottez E, et al. Gut Epub ahead of print: doi:10.1136/gutjnl-2017-315783

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUKVNRWBASRAR
Date   Source Headline
10th May 20247:00 amRNSCompletion of placing
9th May 20244:49 pmRNSProposed REX Retail Offer
9th May 20244:48 pmRNSProposed Fundraise for a minimum of £6.0 million
24th Apr 20243:36 pmRNSClinical Trial Agreement
3rd Apr 20245:00 pmRNSApplication for Listing & Total Voting Rights
3rd Apr 20247:00 amRNSNICE recommends the Genedrive CYP2C19-ID Kit
28th Mar 20247:00 amRNSHalf-year Report
26th Mar 20247:00 amRNSInvestor presentation
19th Mar 20243:53 pmRNSApplication for Listing & Total Voting Rights
15th Mar 202412:30 pmRNSReceipt of R&D tax credit
19th Feb 20247:00 amRNSNICE Early Value Assessment update
6th Feb 20242:03 pmRNSDirector/PDMR Shareholding
2nd Feb 20243:35 pmRNSTotal Voting Rights
19th Jan 20244:14 pmRNSTotal Voting Rights
15th Jan 20243:21 pmRNSTotal Voting Rights
10th Jan 20247:00 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSEquity Prepayment Facility drawdown
29th Dec 202311:44 amRNSResult of AGM
20th Dec 20234:57 pmRNSTotal Voting Rights
20th Dec 20237:00 amRNSInitial overseas orders of MT-RNR1 ID kit
7th Dec 20237:00 amRNSTotal Voting Rights
6th Dec 20237:00 amRNSPosting of annual report and notice of AGM
6th Dec 20237:00 amRNSTotal Voting Rights
4th Dec 20231:13 pmRNSMT-RNR1 ID kit adopted for routine use in Brighton
30th Nov 20235:29 pmRNSBlock listing Interim Review
30th Nov 20237:00 amRNSFinal Results
29th Nov 20235:25 pmRNSEquity Prepayment Facility drawdown
16th Nov 20237:00 amRNSNotice of Results
20th Oct 202310:52 amRNSTotal Voting Rights
28th Sep 202312:35 pmRNSc£1.2m grant awarded
21st Sep 20232:39 pmRNSApplication for listing & total voting rights
11th Sep 20232:17 pmRNSBoard changes
6th Sep 20237:00 amRNSUKCA marking achieved for new CYP2C19 test
4th Aug 20234:00 pmRNSTotal Voting Rights
5th Jul 20239:11 amRNSEquity Prepayment Facility drawdown
16th Jun 20232:28 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSMulti-partner grant awarded
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.